Studying the levels of IL-21 and IL-22 in the serum of breast cancer patients may contribute to a better understanding of the mechanisms underlying the pathogenesis of this tumour type and offer new perspectives on the diagnosis and therapy of breast cancer, including the identification of biomarkers to support personalised treatment. The gene discussed is IL22; the disease is neoplasm.